Management Dilemma in Choosing Evolving Treatments in Neutropenic Septic Shock

Management Dilemma in Choosing Evolving Treatments in Neutropenic Septic Shock | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report Management Dilemma in Choosing Evolving Treatments in Neutropenic Septic Shock H. David Humes, Kera Luckritz, Stephen Gorga, Katie Plomaritas, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6221280/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract How does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the availability of a therapeutic device with a completely new approach to treat sepsis. This device, called the selective cytopheretic device (SCD), is a first-in-class autologous immune cell directed therapy. The SCD, when integrated into an extracorporeal blood circuit, has been shown to bind activated neutrophils and monocytes. With a simple pharmacologic maneuver within the device, the bound cells in real time are immunomodulated from a highly pro-inflammatory state to a less inflammatory phenotype. These transformed cells are then released back into the systemic circulation thereby tempering the systemic hyperinflammatory disorder. Since this cell directed therapy focuses on neutrophils, the processing of these cells in a neutropenic state may be a substantive risk resulting in further immunosuppression. On the other hand, the immunomodulation of the circulating neutrophils and monocytes, although sparse, may be beneficial to disrupt the dysregulated inflammatory state responsible for ongoing tissue damage and organ dysfunction. Prior clinical SCD trials excluded patients with neutropenia so that no prior clinical experience was available to make a difficult decision. This report presents the manner in which the medical team approached these issues and made a therapeutic plan that resulted in a positive clinical outcome for the patient. sepsis neutrophils neutropenia shock immunomodulation extracorporeal device Full Text Additional Declarations The authors declare potential competing interests as follows: H. David Humes and Michael Humes have financial interest in SeaStar Medical, Inc. and Innovative Biotherapies, Inc. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6221280","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":428443989,"identity":"1392d798-04e1-4d31-988e-885e868db5b3","order_by":0,"name":"H. David Humes","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAq0lEQVRIiWNgGAWjYDCCG2DShoGBmYGNAUQSqyWNdC2HQQSRWvhu95hu+PDnfOLaduZnDxgqrBMbCGmRvHPG7ObMttuJ2w6zmRswnEknrMXgRo7Zbd4GkBYeNgnGtsNEavnz5xxUyz9itTCwHYBqaSBCi+SNtLKbvW3JxkC/mEkkHEs3JqiF70byths//tjJbjt/+JnEhxprWYJaUEECacpHwSgYBaNgFOACAAdTRClZSxShAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-4309-1614","institution":"University of Michigan","correspondingAuthor":true,"prefix":"","firstName":"H.","middleName":"David","lastName":"Humes","suffix":""},{"id":428443990,"identity":"99c4771d-c5a8-4fc2-bbf8-b0eada6eb8a5","order_by":1,"name":"Kera Luckritz","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Kera","middleName":"","lastName":"Luckritz","suffix":""},{"id":428443991,"identity":"661fa8c5-ef69-432f-85b4-58cff8642e11","order_by":2,"name":"Stephen Gorga","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Stephen","middleName":"","lastName":"Gorga","suffix":""},{"id":428443992,"identity":"74981edc-6518-4f95-8bea-39783c615daa","order_by":3,"name":"Katie Plomaritas","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Katie","middleName":"","lastName":"Plomaritas","suffix":""},{"id":428443993,"identity":"dbb2688e-1bd7-4dfd-8fbd-098e631cf3f1","order_by":4,"name":"Sara Hoatlin","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Sara","middleName":"","lastName":"Hoatlin","suffix":""},{"id":428443994,"identity":"7be44dfd-0a33-493f-93aa-1a9bd37b8563","order_by":5,"name":"Michael Humes","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Humes","suffix":""},{"id":428443995,"identity":"7a6e8a53-4dab-4835-a901-2d4a125e95c7","order_by":6,"name":"Lenar Yessayan","email":"","orcid":"","institution":"University of Michigan","correspondingAuthor":false,"prefix":"","firstName":"Lenar","middleName":"","lastName":"Yessayan","suffix":""}],"badges":[],"createdAt":"2025-03-13 15:11:55","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":true,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":true,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-6221280/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6221280/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":78500415,"identity":"960a22d2-7e2a-472f-8547-9207e6eef23d","added_by":"auto","created_at":"2025-03-14 06:11:51","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":508271,"visible":true,"origin":"","legend":"","description":"","filename":"ManagementDilemmaNeutropenicSepticShockHumes.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6221280/v1_covered_0edfa535-1d2f-4aa0-a3e1-43af06dc812c.pdf"}],"financialInterests":"The authors declare potential competing interests as follows: H. David Humes and Michael Humes have financial interest in SeaStar Medical, Inc. and\nInnovative Biotherapies, Inc.","formattedTitle":"\u003cp\u003eManagement Dilemma in Choosing Evolving Treatments in Neutropenic Septic Shock\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"University of Michigan Medical School","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"sepsis, neutrophils, neutropenia, shock, immunomodulation, extracorporeal device","lastPublishedDoi":"10.21203/rs.3.rs-6221280/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6221280/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eHow does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the availability of a therapeutic device with a completely new approach to treat sepsis. This device, called the selective cytopheretic device (SCD), is a first-in-class autologous immune cell directed therapy. The SCD, when integrated into an extracorporeal blood circuit, has been shown to bind activated neutrophils and monocytes. With a simple pharmacologic maneuver within the device, the bound cells in real time are immunomodulated from a highly pro-inflammatory state to a less inflammatory phenotype. These transformed cells are then released back into the systemic circulation thereby tempering the systemic hyperinflammatory disorder. Since this cell directed therapy focuses on neutrophils, the processing of these cells in a neutropenic state may be a substantive risk resulting in further immunosuppression. On the other hand, the immunomodulation of the circulating neutrophils and monocytes, although sparse, may be beneficial to disrupt the dysregulated inflammatory state responsible for ongoing tissue damage and organ dysfunction. Prior clinical SCD trials excluded patients with neutropenia so that no prior clinical experience was available to make a difficult decision. This report presents the manner in which the medical team approached these issues and made a therapeutic plan that resulted in a positive clinical outcome for the patient.\u003c/p\u003e","manuscriptTitle":"Management Dilemma in Choosing Evolving Treatments in Neutropenic Septic Shock","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-03-14 06:03:43","doi":"10.21203/rs.3.rs-6221280/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"96460d9d-fbe3-4c5e-8c21-05195f91f64b","owner":[],"postedDate":"March 14th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-03-14T06:03:43+00:00","versionOfRecord":[],"versionCreatedAt":"2025-03-14 06:03:43","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6221280","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6221280","identity":"rs-6221280","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}